Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
Cingulate Inc. CTx-1301 on track to file for Marketing Approval with FDA in 1H 2025 Increase of $10 Million in Stockholders’ Equity KANSAS CITY, Kan., May 08, 2024 (GLOBE NEWSWIRE)…